Comorbidities in patients with Unverricht-Lundborg disease (EPM1)

dc.contributor.authorSipilä Jussi OT
dc.contributor.authorKälviäinen Reetta
dc.contributor.organizationfi=kliiniset neurotieteet|en=Clinical Neurosciences|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.74845969893
dc.converis.publication-id176538645
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/176538645
dc.date.accessioned2022-11-29T14:56:34Z
dc.date.available2022-11-29T14:56:34Z
dc.description.abstract<p><strong>Background: </strong>Unverricht-Lundborg disease (EPM1) typically leads to accumulating disability. Disability may also be caused by comorbidities but there are no data available on these.</p><p><strong>Aims of the study: </strong>To investigate the frequency of comorbidities in EPM1.</p><p><strong>Methods: </strong>Comorbidity data of a previously described cohort of 135 Finnish patients with EPM1 were retrieved from neurological, surgical (including subspecialities), internal medicine (including subspecialities) and intensive care patient charts of the treating hospitals.</p><p><strong>Results: </strong>Mean follow-up time was 31.4 years (SD 12.4 years, range 6.8-57.8 years), during which at least one comorbidity was observed in 107 patients (79%) and three or more in 53 (39%). The most common diagnostic categories were external injuries, mental and behavioural disorders and endocrine, nutritional and metabolic diseases. The most common single comorbid diagnosis was a fracture of the ankle (in 19% of all patients). The second most common single comorbid diagnosis in the cohort was diabetes (in 13% of all patients), and the third was depression, recorded for 13% of the cohort. Malignancies and cardiovascular end-organ damage were rare, whereas phimosis/paraphimosis appeared more common than in general population.</p><p><strong>Conclusions: </strong>Patients with EPM1 often have comorbidities. Trauma and mental health risks should be especially followed and acted upon. Further studies are needed to more accurately comorbidity risks, characteristics and patient needs.</p>
dc.format.pagerange690
dc.format.pagerange693
dc.identifier.jour-issn0001-6314
dc.identifier.olddbid190037
dc.identifier.oldhandle10024/173128
dc.identifier.urihttps://www.utupub.fi/handle/11111/30782
dc.identifier.urnURN:NBN:fi-fe2022110164041
dc.language.isoen
dc.okm.affiliatedauthorSipilä, Jussi
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3112 Neurosciencesen_GB
dc.okm.discipline3112 Neurotieteetfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWILEY
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1111/ane.13706
dc.relation.ispartofjournalActa Neurologica Scandinavica
dc.relation.issue5
dc.relation.volume146
dc.source.identifierhttps://www.utupub.fi/handle/10024/173128
dc.titleComorbidities in patients with Unverricht-Lundborg disease (EPM1)
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Acta Neuro Scandinavica - 2022 - Sipil - Comorbidities in patients with Unverricht Lundborg disease EPM1.pdf
Size:
301.06 KB
Format:
Adobe Portable Document Format